Business Context and Reporting Period
Company: KindlyMD, Inc. (Nasdaq: KDLY)
Filing Type: Form 10-K (Annual Report)
Period: Fiscal year ended December 31, 2024
Business Overview: KindlyMD is a Utah-based healthcare and data company focused on value-based care, specifically targeting the opioid epidemic through integrated behavioral health, pain management, and alternative medicine. The company operates outpatient clinics and telemedicine services, billing Medicare, Medicaid, and commercial insurers. It also collects and analyzes patient data to improve outcomes and reduce opioid reliance.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Net Revenues | $2,719,840 | $3,768,598 |
| Net Loss | $(3,617,647) | $(1,617,461) |
| Loss Per Share (Basic/Diluted) | $(0.67) | $(0.36) |
| Operating Expenses | $6,066,611 | $5,388,818 |
| Cash and Cash Equivalents (End of Period) | $2,273,624 | $525,500 |
| Working Capital | $1,899,602 | $(197,520) Deficit |
| Total Assets | $3,677,992 | $1,099,202 |
| Total Liabilities | $1,109,682 | $1,207,614 |
Material Changes vs. Prior Period
- Revenue Decline: Revenues decreased by 27.8% ($1.05 million) primarily due to the discontinuation of white-labeled retail product sales and a strategic shift from cash-pay services to insurance-billed services. However, insurance reimbursements increased by 1,088% year-over-year.
- Increased Net Loss: Net loss more than doubled to $3.62 million. This was driven by a 12.6% increase in operating expenses, specifically a 40.6% rise in General and Administrative (G&A) costs (due to professional fees and D&O insurance) and a 15,009% increase in Research and Development (R&D) costs related to Enterprise Data Management (EDM) infrastructure.
- Liquidity Improvement: Working capital improved from a deficit of $197,520 in 2023 to a positive $1.9 million in 2024. This was primarily fueled by net proceeds of approximately $5.9 million from the Initial Public Offering (IPO) completed in June 2024.
- Debt Reduction: Total liabilities decreased by 8.1%. The company extinguished derivative liabilities and reduced notes payable following the IPO, offset slightly by increases in operating lease liabilities.
Guidance, Outlook, and Risks
Management Commentary and Outlook
Management views the company as being in the early stages of development. The 2024 focus was on securing in-network status with commercial insurers and building the EDM data infrastructure. For 2025 and beyond, the company plans to:
- Expand insured client bases and integrated behavioral health service offerings.
- Continue developing the medical data set using Large Language Models (LLMs) to analyze patient needs and treatment efficacy.
- Pursue an acquisition growth strategy, though no specific targets are currently identified.
- Expand service lines within Utah; no concrete plans for expansion into other states exist due to complex regulatory landscapes.
Risks and Contingencies
- Regulatory Risk (Cannabis): The company operates adjacent to the medical cannabis industry (selling hemp/CBD products). While compliant with Utah state law, these activities conflict with federal law (Controlled Substances Act), creating a risk of federal enforcement, asset seizure, or criminal penalties.
- Internal Control Weaknesses: Management concluded that internal control over financial reporting was not effective as of December 31, 2024, due to material weaknesses. Remediation plans are underway, including engaging consultants and documenting policies.
- Liquidity and Capital Needs: Despite the IPO proceeds, the company expects to require additional financing in the future to support working capital and growth, which may be dilutive or costly.
- Profitability Uncertainty: The business model relies on a limited number of initiatives, leading to potential volatility in revenues and earnings. The company has not yet achieved profitability.
Investor Verification Checklist
- Internal Controls: Verify the progress of remediation plans for the material weaknesses in internal controls over financial reporting.
- Regulatory Compliance: Monitor any federal enforcement actions or changes in state/federal cannabis regulations that could impact the company's retail product sales.
- Insurance Contracts: Confirm the stability and renewal rates of contracts with major commercial payers (Medicare, Medicaid, Blue Cross, Cigna) as the company shifts away from cash-pay models.
- Data Monetization: Assess the timeline and feasibility of generating revenue from the Enterprise Data Management (EDM) platform, as this is a key future growth driver but currently incurs high R&D costs.
- Cash Burn Rate: Track the rate of cash consumption against the $2.27 million cash balance to determine the runway before additional capital raises are required.